These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23795713)

  • 21. Adherent-Invasive E. coli enhances colonic hypersensitivity and P2X receptors expression during post-infectious period.
    Lashermes A; Boudieu L; Barbier J; Sion B; Gelot A; Barnich N; Ardid D; Carvalho FA
    Gut Microbes; 2018 Jan; 9(1):26-37. PubMed ID: 28806140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural and adhesive properties of the long polar fimbriae protein LpfD from adherent-invasive Escherichia coli.
    Coppens F; Iyyathurai J; Ruer S; Fioravanti A; Taganna J; Vereecke L; De Greve H; Remaut H
    Acta Crystallogr D Biol Crystallogr; 2015 Aug; 71(Pt 8):1615-26. PubMed ID: 26249343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ribonucleotide reductase NrdR as a novel regulator for motility and chemotaxis during adherent-invasive Escherichia coli infection.
    Dreux N; del Mar Cendra M; Massier S; Darfeuille-Michaud A; Barnich N; Torrents E
    Infect Immun; 2015 Apr; 83(4):1305-17. PubMed ID: 25605769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sites for Dynamic Protein-Carbohydrate Interactions of O- and C-Linked Mannosides on the E. coli FimH Adhesin.
    Touaibia M; Krammer EM; Shiao TC; Yamakawa N; Wang Q; Glinschert A; Papadopoulos A; Mousavifar L; Maes E; Oscarson S; Vergoten G; Lensink MF; Roy R; Bouckaert J
    Molecules; 2017 Jul; 22(7):. PubMed ID: 28671638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crohn's disease-associated adherent-invasive Escherichia coli adhesion is enhanced by exposure to the ubiquitous dietary polysaccharide maltodextrin.
    Nickerson KP; McDonald C
    PLoS One; 2012; 7(12):e52132. PubMed ID: 23251695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI.
    Jarvis C; Han Z; Kalas V; Klein R; Pinkner JS; Ford B; Binkley J; Cusumano CK; Cusumano Z; Mydock-McGrane L; Hultgren SJ; Janetka JW
    ChemMedChem; 2016 Feb; 11(4):367-73. PubMed ID: 26812660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crohn disease-associated Escherichia coli promote gastrointestinal inflammatory disorders by activation of HIF-dependent responses.
    Mimouna S; Gonçalvès D; Barnich N; Darfeuille-Michaud A; Hofman P; Vouret-Craviari V
    Gut Microbes; 2011; 2(6):335-46. PubMed ID: 22157238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycopolymers as Antiadhesives of E. coli Strains Inducing Inflammatory Bowel Diseases.
    Yan X; Sivignon A; Yamakawa N; Crepet A; Travelet C; Borsali R; Dumych T; Li Z; Bilyy R; Deniaud D; Fleury E; Barnich N; Darfeuille-Michaud A; Gouin SG; Bouckaert J; Bernard J
    Biomacromolecules; 2015 Jun; 16(6):1827-36. PubMed ID: 25961760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The interaction of Crohn's disease-associated Escherichia coli to Peyer's patches of the intestinal mucosa involves long polar fimbriae].
    Chassaing B; Darfeuille-Michaud A
    Med Sci (Paris); 2011; 27(6-7):572-3. PubMed ID: 21718635
    [No Abstract]   [Full Text] [Related]  

  • 30. Characterization of adherent-invasive Escherichia coli isolated from pediatric patients with inflammatory bowel disease.
    Negroni A; Costanzo M; Vitali R; Superti F; Bertuccini L; Tinari A; Minelli F; Di Nardo G; Nuti F; Pierdomenico M; Cucchiara S; Stronati L
    Inflamm Bowel Dis; 2012 May; 18(5):913-24. PubMed ID: 21994005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex.
    Wellens A; Garofalo C; Nguyen H; Van Gerven N; Slättegård R; Hernalsteens JP; Wyns L; Oscarson S; De Greve H; Hultgren S; Bouckaert J
    PLoS One; 2008 Apr; 3(4):e2040. PubMed ID: 18446213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.
    Mydock-McGrane LK; Cusumano ZT; Janetka JW
    Expert Opin Ther Pat; 2016; 26(2):175-97. PubMed ID: 26651364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation.
    Klein T; Abgottspon D; Wittwer M; Rabbani S; Herold J; Jiang X; Kleeb S; Lüthi C; Scharenberg M; Bezençon J; Gubler E; Pang L; Smiesko M; Cutting B; Schwardt O; Ernst B
    J Med Chem; 2010 Dec; 53(24):8627-41. PubMed ID: 21105658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the carbohydrate recognition domain of the bacterial adhesin FimH: Design, synthesis and binding properties of mannoside ligands.
    Sperling O; Fuchs A; Lindhorst TK
    Org Biomol Chem; 2006 Nov; 4(21):3913-22. PubMed ID: 17047870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of an aggregation assay to screen FimH antagonists.
    Abgottspon D; Rölli G; Hosch L; Steinhuber A; Jiang X; Schwardt O; Cutting B; Smiesko M; Jenal U; Ernst B; Trampuz A
    J Microbiol Methods; 2010 Sep; 82(3):249-55. PubMed ID: 20620174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The tyrosine gate as a potential entropic lever in the receptor-binding site of the bacterial adhesin FimH.
    Wellens A; Lahmann M; Touaibia M; Vaucher J; Oscarson S; Roy R; Remaut H; Bouckaert J
    Biochemistry; 2012 Jun; 51(24):4790-9. PubMed ID: 22657089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition profiles of mono- and polyvalent FimH antagonists against 10 different Escherichia coli strains.
    Chalopin T; Brissonnet Y; Sivignon A; Deniaud D; Cremet L; Barnich N; Bouckaert J; Gouin SG
    Org Biomol Chem; 2015 Dec; 13(46):11369-75. PubMed ID: 26440382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-based drug design and optimization of mannoside bacterial FimH antagonists.
    Han Z; Pinkner JS; Ford B; Obermann R; Nolan W; Wildman SA; Hobbs D; Ellenberger T; Cusumano CK; Hultgren SJ; Janetka JW
    J Med Chem; 2010 Jun; 53(12):4779-92. PubMed ID: 20507142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist.
    Spaulding CN; Klein RD; Ruer S; Kau AL; Schreiber HL; Cusumano ZT; Dodson KW; Pinkner JS; Fremont DH; Janetka JW; Remaut H; Gordon JI; Hultgren SJ
    Nature; 2017 Jun; 546(7659):528-532. PubMed ID: 28614296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of mucosa-associated Escherichia coli strains isolated from Crohn's disease patients in Brazil.
    Costa RFA; Ferrari MLA; Bringer MA; Darfeuille-Michaud A; Martins FS; Barnich N
    BMC Microbiol; 2020 Jun; 20(1):178. PubMed ID: 32576138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.